末消動脈疾患（PAD）治療薬の世界市場予測および分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 12
1.1 List of Tables 18
1.2 List of Figures 22
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 30
3.2 Classification and Staging Systems 31
3.3 Symptoms and Clinical Presentation 33
3.4 Prognosis 37
3.5 Quality of Life 41
4 Epidemiology 43
4.1 Disease Background 43
4.2 Risk Factors and Comorbidities 44
4.3 Global Trends 46
4.4 Forecast Methodology 47
4.4.1 Sources Used 48
4.4.2 Sources Not Used 61
4.4.3 Forecast Assumptions and Methods 61
4.5 Epidemiological Forecast of Total Prevalent Cases of PAD (2014-2024) 67
4.5.1 Total Prevalent Cases of PAD 67
4.5.2 Age-Specific Total Prevalent Cases of PAD 68
4.5.3 Sex-Specific Total Prevalent Cases of PAD 70
4.5.4 Age-Adjusted Total Prevalence of PAD 72
4.5.5 Total Prevalent Asymptomatic and Symptomatic Cases of PAD 73
4.5.6 Total Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia 75
4.5.7 Proportion of Total PAD Cases that Present as Asymptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia 77
4.5.8 Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes 78
4.6 Epidemiological Forecast of Diagnosed Prevalent Cases of PAD (2014-2024) 80
4.6.1 Diagnosed Prevalent Cases of PAD 80
4.6.2 Age-Specific Diagnosed Prevalent Cases of PAD 82
4.6.3 Sex-Specific Diagnosed Prevalent Cases of PAD 84
4.6.4 Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD 86
4.6.5 Diagnosed Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia 88
4.6.6 Proportion of Diagnosed PAD Cases that Present as Symptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia 90
4.6.7 Diagnosed Prevalent Cases of PAD with Hypertension and PAD Cases with Diabetes 91
4.7 Discussion 93
4.7.1 Epidemiological Forecast Insight 93
4.7.2 Limitations of the Analysis 94
4.7.3 Strengths of the Analysis 95
5 Disease Management 96
5.1 Diagnosis and Treatment Overview 96
5.1.1 Diagnosis 96
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 100
5.2 US 101
5.3 Five Major European Markets 108
5.4 Japan 118
5.5 Urban China 122
6 Competitive Assessment 128
6.1 Overview 128
6.2 Lifestyle Modifications 132
6.2.1 Exercise 132
6.2.2 Smoking cessation 135
6.3 Risk Factor Modification Drugs 137
6.3.1 Lipid-Lowering Medical Therapies 137
6.3.2 Antihypertensive Medical Therapies 144
6.3.3 Antithrombotic Medical Therapies 151
6.3.4 Glucose-Lowering Medical Therapies 172
6.3.5 Thrombolytic Therapies 175
6.4 Medical Therapies Treating the Symptoms of PAD – Major Brands 176
6.4.1 Pletal / Pletaal (cilostazol) 176
6.4.2 Praxilene (naftidrofuryl oxalate) 190
6.4.3 Trental (pentoxifylline) 196
6.4.4 Prostaglandin and Prostanoid Medical Therapies 205
6.4.5 Other Pharmacological Therapies 209
6.5 Non-Pharmacological Therapies 211
6.5.1 Revascularization 211
7 Unmet Need and Opportunity Analysis 217
7.1 Overview 217
7.2 Enhanced Patient and Physician Education and Awareness of PAD, Facilitating Augmented Diagnosis and Treatment Rates 219
7.2.1 Unmet Need 219
7.2.2 Gap Analysis 226
7.2.3 Opportunity 228
7.3 A Greater Number of Trials Exclusively Involving PAD Patients Will Yield Improved Guidelines for the Management of PAD 233
7.3.1 Unmet Need 233
7.3.2 Gap Analysis 237
7.3.3 Opportunity 238
7.4 Superior Pharmacological Agents that Treat the Symptoms of Intermittent Claudication and Critical Limb Ischemia, but also Obviate Cardiovascular Events 240
7.4.1 Unmet Need 240
7.4.2 Gap Analysis 242
7.4.3 Opportunity 243
7.5 Unravelling the Convoluted Nature Behind the Etiology and Pathophysiology of Atherosclerosis, Which Will Potentially Lead to Treatments that Prevent or Reverse Plaque Formation 247
7.5.1 Unmet Need 247
7.5.2 Gap Analysis 248
7.5.3 Opportunity 248
8 Pipeline Assessment 251
8.1 Overview 251
8.2 Promising Drugs in Late-Stage Clinical Development 253
8.2.1 Xarelto (rivaroxaban) 254
8.2.2 Brilinta (ticagrelor) 270
8.3 Promising Drugs in Early-Stage Clinical Development 286
8.3.1 Therapeutic Angiogenesis 286
9 Current and Future Players 291
9.1 Overview and Trends in Corporate Strategy 291
9.2 Company Profiles 295
9.2.1 Bayer 295
9.2.2 Janssen (Johnson & Johnson) 297
9.2.3 AstraZeneca 299
9.2.4 Merck & Co. 302
9.2.5 Sanofi 303
9.2.6 Pfizer 305
9.2.7 Bristol-Myers Squibb 306
9.2.8 Otsuka Holdings 307
10 Market Outlook 309
10.1 Global Markets 309
10.1.1 Forecast 309
10.1.2 Drivers and Barriers – Global Issues 314
10.2 US 318
10.2.1 Forecast 318
10.2.2 Key Events 322
10.2.3 Drivers and Barriers 322
10.3 Five Major European Markets 326
10.3.1 Forecast 326
10.3.2 Key Events 330
10.3.3 Drivers and Barriers 331
10.4 Japan 341
10.4.1 Forecast 341
10.4.2 Key Events 344
10.4.3 Drivers and Barriers 344
10.5 Urban China 347
10.5.1 Forecast 347
10.5.2 Key Events 350
10.5.3 Drivers and Barriers 350
11 Appendix 354
11.1 Bibliography 354
11.2 Abbreviations 382
11.3 Methodology 387
11.4 Forecasting Methodology 387
11.4.1 Diagnosed PAD Patients 387
11.4.2 Percent Drug-Treated Patients 388
11.4.3 Drugs Included in Each Therapeutic Class 388
11.4.4 Launch and Patent Expiry Dates 388
11.4.5 General Pricing Assumptions 389
11.4.6 Individual Drug Assumptions 390
11.4.7 Generic Erosion 395
11.4.8 Pricing of Pipeline Agents 395
11.5 Physicians and Specialists Included in this Study 396
11.6 About the Authors 400
11.6.1 Analyst 400
11.6.2 Therapy Area Director 400
11.6.3 Epidemiologist 401
11.6.4 Global Head of Healthcare 401
11.6.5 Global Director of Therapy Analysis and Epidemiology 402
11.7 About GlobalData 403
11.8 Disclaimer 403